N4 Pharma Plc (AIM:N4P) Results of latest nuvec pre-clinical study

N4 Pharma Plc (AIM: N4P), a specialist pharmaceutical company which reformulates existing drugs and vaccines to improve their performance, announces the results of the latest study it has conducted for its nuvec® silica nanoparticles (“SiNPs”) delivery system.

As well as investigating tolerability, the objective of this study (funded via a biomedical Catalyst Grant) was to determine the in-vivo capacity for the Company’s SiNPs to deliver DNA to generate local expression of a protein. This is a key indicator as to whether a vaccine delivery system is likely to successfully generate an immune response. The Company completed two tests in this study, the first was an injection directly into a cancerous tumour and the second was a subcutaneous injection; two routes of administration typically used for vaccination.

In conclusion, a single injection of the SiNPs is effective in delivering DNA to generate localised protein expression at the site of the injection and draining lymph nodes and release cytokines into the systemic circulation. These are all crucial elements for successful cancer therapy treatment. No tolerability issues were encountered for the duration of the study.

Following these results, further in-vivo studies will be conducted to demonstrate the capability of the Company’s SiNPs to deliver specific antigens to promote an adaptive immune response (i.e. as a vaccine) or to deliver functional proteins that can have a biological effect and to undertake comparison studies showing how the Company’s SiNPs compare to lipid nanoparticles, which are widely used as delivery systems for cancer vaccines and therapies.

Nigel Theobald, CEO of N4 Pharma, commented:

“As well as preparing to take our sildenafil reformulation into clinic, we have been scoping out the potential for our nuvec® delivery system and continue to make encouraging progress demonstrating its capability. This signifies another prominent step forward on the road to commercialising nuvec® .

We now have evidence that our SiNPs have many desirable features for use in either a vaccine approach or to deliver therapeutic proteins to tissues and are uncovering key commercial advantages compared to lipid nanoparticles. This increases the scope of nuvec’s® application which in turn enhances the value of the technology to potential commercial partners.

The value of the global nanotechnology drug delivery market is forecast to grow from $4.1 billion in 2014 to $11.9 billion in 2023*.

As nuvec® continues to meet its technical targets, it becomes very clear that we have the potential to become a significant player in this growing market. We will continue its development to determine how best to compete and to take the technology forward.”

* source: Transparency Market Research July 2014

Linking Shareholders and Executives :Share Talk

If anyone reads this article found it useful, helpful? Then please subscribe www.share-talk.com or follow SHARE TALK on our Twitter page for future updates.

Terms of Website Use

All information is provided on an as-is basis. Where we allow Bloggers to publish articles on our platform please note these are not our opinions or views and we have no affiliation with the companies mentioned

Share Talk Investor Show - September 27th August 2019

Malcare WordPress Security